United States Gene Therapy Markets, 2022-2027: Introduction of Universal Car-T Therapy, Increase in Strategic Acquisitions, and Increase in R&D Funding

DUBLIN, April 06, 2022–(COMMERCIAL WIRE)–The “US Gene Therapy Market – Industry Outlook and Forecast 2022-2027” Report has been added to ResearchAndMarkets.com offering

The US gene therapy market is expected to grow at a CAGR of 43.44% during 2022-2027. The US gene therapy market would achieve an absolute growth of more than 771.00% in terms of revenue between 2021 and 2027.

In-depth analysis and data-driven insights on the impact of COVID-19 included in this US Gene Therapy Market Report.

The market is experiencing constant growth due to the increased availability of funds from various public and private institutes. In addition, there is increased support from regulatory bodies for product approvals and the provision of fast track designations for products, which encourages suppliers to manufacture products at a faster rate.


Among product type segments, the CAR-T therapy segment dominates the US gene therapy market with a 51.96% share, followed by non-CAR-T therapy with 48.04% in 2021.

Based on vector type, the US gene therapy market is segmented into retroviral and others. The other segment includes adenoviruses, adeno-associated viruses, herpes simplex viruses, and non-viral vectors. The retroviral segment represented a majority share of 51.96% and others with 48.04% in 2021

Based on end users, the market is segmented into hospitals, cancer care centers, and academic and research centers. The hospital segment dominated the market with a 56.45% share, followed by cancer care centers with 35.87%.


The US gene therapy market is seeing intense competition among providers. The market is characterized by the presence of several small-scale and pharmaceutical companies. With the changing market landscape, competition is becoming intense due to some recent high-value mergers and acquisitions.


  • Increasing market access for gene therapies

  • Introduction of Universal Car-T therapy

  • Increase in strategic acquisitions

  • Increased funding for gene therapy R&D activities

Key Company Profiles

  • Amgen

  • Blue Bird Biography

  • bristol myers squibb

  • Sciences of Gilead

  • Novartis

  • F. Hoffmann-La Roche

Gene therapy research companies

  • 4Dmt

  • Abeona Therapeutics

  • angels

  • Question bio

  • Astellas Gene Therapies

  • Autolus therapeutics

  • Therapeutic Candle

  • Castle Creek Biological Sciences

  • Cellectis

  • Evox Therapeutics

  • Free line therapy

  • Gene biotherapy

  • generation biography

  • Gensight Biologics

  • helixsmith

  • Janssen Pharmaceuticals

  • Kolon tissue gene

  • Krystal Biotechnology

  • meiragtx

  • garden therapy

  • Pfizer

  • Poseida Therapeutics

  • organic pass

  • Regenxbio

  • Sana’a Biotechnology

  • Sarepta Therapeutics

  • Stridebio

  • Solid Biosciences

  • Vbl Therapeutics

  • Voyager Therapeutics

  • Unique

Key Topics Covered:

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope and Coverage

4.1 Market definition

4.2 Base year

4.3 Scope of the Study

5 Report assumptions and caveats

5.1 Key Warnings

5.2 Currency conversion

5.3 Market drift

6 Market at a glance

7 Introduction

7.1 Background

7.2 Gene therapy: an overview

8 Reimbursement for gene therapy in the US.

8.1 Summary

9 Regulatory scenario for gene therapy products

9.1 Summary

9.2 Clinical trial process for gene therapy

10 Commercial Gene Therapy Products in the US

10.1 Summary

11 gene therapy products in the works

11.1 Summary

12 market opportunities and trends

12.1 Increased market access for gene therapies

12.2 Introduction of Universal Car-T therapy

12.3 Increase in Strategic Acquisitions

12.4 Increased funding for gene therapy R&D activities

13 market growth enablers

13.1 Augmentation of CMOS to manufacture gene therapies

13.2 Increasing the target patient population

13.3 Product Launches and Regulatory Approvals

13.4 Regulatory support and special designations for gene therapies

14 Market restrictions

14.1 High cost of gene therapy products

14.2 Limitations of gene therapy products

14.3 Availability of Alternative Therapies and Product Recalls

15 Market Overview

15.1 Market Overview

15.2 Market Size and Forecast

15.3 Five Forces Analysis

16 types of vectors

16.1 Market Snapshot and Growth Driver

16.2 Market Overview

16.3 Retrovirals

16.4 Other vectors

17 Product Type

17.1 Market Snapshot and Growth Driver

17.2 Market Overview

17.3 Car-T Therapy

17.4 Therapy without car-T

18 Indication

18.1 Market Snapshot and Growth Driver

18.2 Market Overview

18.3 Oncology

18.4 Others

19 Gene Transfer

19.1 Market Snapshot and Growth Driver

19.2 Market overview

19.3 Ex-Alive

19.4 In vivo

20 end users

20.1 Market Snapshot and Growth Driver

20.2 Market overview

20.3 Hospitals

20.4 Cancer Care Centers

20.5 Academic and Research Centers

21 Competitive Landscape

21.1 Overview of the competition

21.2 Market share analysis

For more information on this report, visit https://www.researchandmarkets.com/r/j4egrk

View the source version on businesswire.com: https://www.businesswire.com/news/home/20220406005780/en/


Laura Wood, Senior Press Officer
For business hours EST call 1-917-300-0470
For US/Canada call toll free 1-800-526-8630
For GMT business hours call +353-1-416-8900

Leave a Reply

Your email address will not be published.